ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.00
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,851.55
      0.69%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. INmune Bio Inc (INMB)

      7. INmune Bio Inc (INMB) News

      INMB

      INmune Bio (INMB)

      INmune Bio Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INMB
      DateTimeSourceHeadlineSymbolCompany
      04/25/20249:00AMGlobeNewswire Inc.INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:INMBINmune Bio Inc
      04/23/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayNASDAQ:INMBINmune Bio Inc
      04/22/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingNASDAQ:INMBINmune Bio Inc
      04/08/20248:00AMGlobeNewswire Inc.INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024NASDAQ:INMBINmune Bio Inc
      03/28/20244:01PMGlobeNewswire Inc.INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateNASDAQ:INMBINmune Bio Inc
      03/26/20244:01PMGlobeNewswire Inc.INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28NASDAQ:INMBINmune Bio Inc
      03/13/20248:00AMGlobeNewswire Inc.INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyNASDAQ:INMBINmune Bio Inc
      03/05/20248:00AMGlobeNewswire Inc.INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™NASDAQ:INMBINmune Bio Inc
      02/12/20249:00AMGlobeNewswire Inc.INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:INMBINmune Bio Inc
      02/06/20249:00AMGlobeNewswire Inc.INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024NASDAQ:INMBINmune Bio Inc
      01/30/20248:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      01/30/20248:00AMGlobeNewswire Inc.INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease ProgramNASDAQ:INMBINmune Bio Inc
      01/16/20248:30AMGlobeNewswire Inc.ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyNASDAQ:INMBINmune Bio Inc
      01/02/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      01/02/20248:00AMGlobeNewswire Inc.INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:INMBINmune Bio Inc
      12/18/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      12/18/20234:05PMEdgar (US Regulatory)Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]NASDAQ:INMBINmune Bio Inc
      12/18/20234:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      12/18/20234:01PMGlobeNewswire Inc.INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDANASDAQ:INMBINmune Bio Inc
      11/29/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      11/29/20238:00AMGlobeNewswire Inc.INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer SymposiumNASDAQ:INMBINmune Bio Inc
      11/27/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      11/27/20238:00AMGlobeNewswire Inc.INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s DiseaseNASDAQ:INMBINmune Bio Inc
      11/15/20234:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      11/15/20239:00AMGlobeNewswire Inc.INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in EuropeNASDAQ:INMBINmune Bio Inc
      11/13/202311:31AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INMBINmune Bio Inc
      11/01/20234:13PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
      11/01/20234:10PMGlobeNewswire Inc.INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business UpdateNASDAQ:INMBINmune Bio Inc
      11/01/20234:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INMBINmune Bio Inc
      10/31/20234:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INMBINmune Bio Inc
       Showing the most relevant articles for your search:NASDAQ:INMB